Cost Savings Matrix – ENGLAND
Generic name (MIMS) ethinylestradiol / progestogen
Desogestrel 75 microgram
Company
Other
manufacturers
brand
Other brand
cost for 3
cycle pack1
Schering- Plough Ltd
Cerazette®
£8.68
Bayer Healthcare
Microgynon® 30
£2.82
Pfizer Ltd
Ovranette®
£2.20
Morningside Healthcare Ltd
Levest®
£3.00
Ethinylestradiol 30 microgram /
desogestrel 150 microgram
Schering-Plough Ltd
Marvelon®
£6.45
Ethinylestradiol 20 microgram /
desogestrel 150 microgram
Schering-Plough Ltd
Mercilon®
£7.67
Ethinylestradiol 30 microgram /
gestodene 75 microgram
Bayer Healthcare
Femodene®
£6.73
Stragen UK Ltd
Katya®
£5.03
Ethinylestradiol 20 microgram /
gestodene 75 microgram
Bayer Healthcare
Femodette®
£8.85
Stragen UK Ltd
Sunya®
£6.62
Logynon®
£3.82
Ethinylestradiol 30 microgram /
levonorgestrel 150 microgram
Ethinylestradiol 30 / 40 / 30 microgram /
Bayer Healthcare
levonorgestrel 50 / 75 / 125 microgram
References
1. Chemist & Druggist December 2012
2. Data on file based on 2011 PCA data England
Consilient Health
brand (CH)
CH brand
cost for 3
cycle pack 1
% difference
Annual volume
of 3 cycle packs
in England 2
Total potential annual
savings to NHS England
by changing to CH brand
£4.30
50.46%
2,099,352
£9,195,161.76
£1.89
33%
3,335,858
£3,102,347.94
£1.89
14%
301,098
£93,340.38
£1.89
37%
63,404
£70,378.44
Gedarel® 30/150
£4.93
24%
282,579
£429,520.08
Gedarel® 20/150
£5.98
22%
173,443
£293,118.67
£4.85
28%
250,971
£471,825.48
£4.85
4%
1,192
£214.56
£6.37
28%
102,283
£253,661.84
£6.37
4%
1,245
£311.25
£2.87
25%
182,393
£173,273.35
Cerelle®
Rigevidon®
Millinette® 30/75
Millinette® 20/75
TriRegol®
Total potential annual savings to NHS England
by changing to all CH brands
% potential annual savings to NHS England
by changing to all CH brands
For further information and to download the free ‘My OC’ reminder app, please visit: www.knowyourcontraceptives.co.uk
£14,083,154
40%
Cost Savings Matrix – ENGLAND
Abbreviated Prescribing Information – for full prescribing information, including side
effects, precautions and contra-indications, see Summary of Product Characteristics
(SmPC)
Product Name: Rigevidon Coated Tablets. Composition: 1 tablet contains 30 micrograms
ethinylestradiol and 150 micrograms levonorgestrel. Gedarel 30/150 microgram Film-coated
Tablets. Composition: 1 tablet contains 30 micrograms ethinylestradiol and 150 micrograms
desogestrel. Gedarel 20/150 microgram Film-Coated Tablets. Composition: 1 tablet contains
20 micrograms ethinylestradiol and 150 micrograms desogestrel. Millinette 30/75 microgram
Coated Tablets. Composition: 1 tablet contains 30 micrograms ethinylestradiol and 75
micrograms gestodene. Millinette 20/75 microgram Coated Tablets. Composition: 1 tablet
contains 20 micrograms ethinylestradiol and 75 micrograms gestodene. TriRegol Coated
Tablets. Composition: Each pink tablet contains 30 micrograms ethinylestradiol and 50
micrograms levonorgestrel; each white tablet contains 40 micrograms ethinylestradiol and 75
micrograms levonorgestrel; each ochre tablet contains 30 micrograms ethinylestradiol and
125 micrograms levonorgestrel. Cerelle 75 microgram film-coated Tablets. Composition:
One tablet contains 75 micrograms desogestrel. Please refer to the relevant Summary of
Product Characteristics (SmPC) for a full list of excipients. Indication: Oral contraception.
Dosage and Administration: Rigevidon, Gedarel 30/150, Gedarel 20/150, Millinette 30/75,
Millinette 20/75, TriRegol: One tablet is to be taken daily for 21 consecutive days, starting on
day 1 of the normal cycle. Every subsequent pack is started after a 7-day tablet free interval,
during which time a withdrawal bleed usually occurs. Bleeding usually starts on the 2nd or 3rd
day after the last tablet and may not end before the next pack is started. For details of usage,
especially where a patient either misses a dose or has vomiting/diarrhoea, please refer to the
relevant SmPC. Gedarel 30/150, Gedarel 20/150: No data are available on safety and efficacy
of desogestrel in adolescents below 18 years. Cerelle: One tablet taken each day continuously,
without taking any notice of possible bleeding. Each new pack to be started directly after the
previous one. The first tablet should be taken on the first day of menstrual bleeding. If changing
from another contraceptive method, Cerelle should be started on the day after the last active
tablet of a combined oral contraceptive (COC), at any time if the woman is on a progestogen
only pill (POP), on the day of removal of a vaginal ring/transdermal patch/implant/IUS or when
the next injectable is due. For details of usage, especially where a patient either misses a dose
or has vomiting/diarrhoea, please refer to the SmPC. Contraindications: Rigevidon, Gedarel
30/150, Gedarel 20/150, Millinette 30/75, Millinette 20/75, TriRegol: Combined oral
contraceptives (COCs) should not be used if present or previous venous or arterial thrombosis,
(e.g. pulmonary embolism, myocardial infarction (MI) or cerebrovascular disorder/accident),
present or previous prodromal symptoms of thrombosis, (e.g. transient cerebral ischaemia/
attack or angina pectoris), considerable or multiple risk factors for venous or arterial thrombosis
or a predisposition to either condition (please refer to the relevant SmPC), cardiovascular
disorders, (e.g. cardiac diseases, valvulopathy, arrhythmic disturbances), ocular disorder of
vascular origin, severe hypertension, diabetes complicated with angiopathy, migraine with
focal neurological symptoms, pancreatitis with severe hypertriglyceridaemia, severe or recent
hepatic disorders, liver tumours, undiagnosed vaginal bleeding, sex-steroid influenced
malignancies, (e.g. breast or endometrial), or a hypersensitivity to the components of the tablet.
Cerelle: Hypersensitivity to desogestrel or any of the excipients of Cerelle; active venous
thromboembolic disorder; presence or history of severe hepatic disease (whilst liver function
tests are abnormal); known or suspected sex-steroid sensitive malignancies; undiagnosed
vaginal bleeding. Warnings and Precautions: Rigevidon, Gedarel 30/150, Gedarel 20/150,
Millinette 30/75, Millinette 20/75, TriRegol: Prior to starting or resuming use a complete
history should be taken, a physical examination performed and pregnancy ruled out. The
woman should be instructed to carefully read the user leaflet and adhere to the advice. The
benefits of COC use must be weighed against possible risks in each individual case and
discussed with the woman with respect to the following conditions: Circulatory disorders:
Venous or arterial thromboembolism including MI or transient ischaemic attack/stroke. Please
refer to the relevant SmPC for associated risk factors and symptomology associated with the
above conditions. Tumours: A possible increased risk of cervical cancer has been reported
with all long-term COC use. Breast cancer has been reported in COC users, though no direct
causation has been shown. Hepatic tumours have also been reported. Other Conditions:
Clinically relevant increases in blood pressure (rare) and pancreatitis in the presence of or with
a family history of hypertriglyceridaemia have also been reported as have an influence on
peripheral insulin resistance and glucose tolerance, Crohn’s disease and ulcerative colitis. The
following conditions may arise or worsen during use of COCs although evidence of a
relationship is inconclusive: Jaundice and/or pruritus associated with cholestasis, development
of gallstones, porphyria, system lupus erythematosis, haemolytic uraemic syndrome,
Sydenham’s chorea, herpes gestationis, hearing loss due to otosclerosis. COCs should be
stopped and an alternative contraceptive method used in women with: an increase in the
frequency or severity of migraine, impaired liver function (until tests return to normal), severe
depression (until the cause is identified), or persistent clinical hypertension. Please refer to the
relevant SmPC for further details. Bleeding: With all COCs, irregular bleeding may occur,
especially during the first months of use. The evaluation of any irregular bleeding should be
considered after approximately three cycles. If bleeding irregularities occur after previously
regular cycles, adequate diagnostic measures should be taken to exclude malignancy or
pregnancy. Please refer to the relevant SmPC for further information regarding cycle control.
Cerelle: The benefits of progestogen use should be weighed against the possible risks for each
individual woman. The risk of breast cancer is slightly increased with COC use, but for POPs
the evidence is less conclusive. A benefit/risk assessment should be made in women with liver
cancer since progestogens may affect this. Women should be referred to a specialist if acute
or chronic disturbances of liver function occur. Cerelle should be discontinued in the event of
a thrombosis and women with a history of thrombo-embolic disorders should be made aware
of the possibility of a recurrence. Discontinuation of Cerelle should also be considered if there
is long-term immobilization. Diabetic patients should be carefully observed during the first
months of use due to a potential effect on insulin resistance and glucose tolerance. If sustained
hypertension develops, or if a significant increase in blood pressure does not adequately
respond to antihypertensive therapy, consider discontinuing Cerelle. Ectopic pregnancy should
be included in the differential diagnosis if a woman gets amenorrhoea or abdominal pain.
Chloasma may occasionally occur, and women with a tendency to this should avoid exposure
to the sun or UV radiation whilst taking Cerelle. The following conditions have been reported
during sex steroid use: jaundice and/or pruritus related to cholestasis; gallstone formation;
porphyria; systemic lupus erythematosus; haemolytic uraemic syndrome; Sydenham’s chorea;
herpes gestationis; otosclerosis-related hearing loss; (hereditary) angioedema. Women with
certain rare hereditary problems of carbohydrate metabolism should not take Cerelle since
this contains lactose. Pregnancy and lactation: Rigevidon, Gedarel 30/150, Gedarel 20/150,
Millinette 30/75, Millinette 20/75, TriRegol: The COCs are not indicated during pregnancy;
treatment should be withdrawn immediately if pregnancy occurs. The use of COCs is not
recommended during breast feeding. Cerelle: Cerelle is not indicated during pregnancy and
treatment should be stopped if pregnancy occurs. Cerelle may be used during lactation; the
development and growth of a nursing infant, whose mother uses Cerelle should, however, be
carefully observed. Effects on ability to drive and use machinery: There is no influence on
the ability to drive and use machines. Undesirable effects: Rigevidon, Gedarel 30/150,
Gedarel 20/150, Millinette 30/75, Millinette 20/75, TriRegol: The following adverse reactions
have been reported in women using COCs: Very common (>1/10): irregular bleeding, nausea,
weight increase, breast tenderness and headache. These usually occur at the beginning of
treatment and are transient. Other common (>1/100, <1/10): fluid retention, changes to libido,
mood changes including depression, irritability, dizziness, nervousness, corneal disorder, ocular
irritation in contact lens wearers, visual disturbance, migraine, hypertension, abdominal pain,
vomiting, cholelithiasis, acne, chloasma, rash, urticaria, amenorrhoea, hypomenorrhoea,
dysmenorrhoea, metrorrhagia, changes in cervical ectropion and secretion, breast pain,
enlargement or secretion and weight decrease. Venous and arterial thromboembolic disorders,
cervical cancer, liver tumours and erythema nodosum have also been reported with COC use.
Cerelle: The most commonly reported is bleeding irregularity but after a couple of months of
treatment, bleedings tend to become less frequent. The following adverse reactions have been
reported: Common (>1/100, <1/10): mood altered, libido decreased, depressed mood,
headache, nausea, acne, breast pain, menstruation irregular, amenorrhoea, weight increased.
Uncommon (>1/1,000, <1/100): Vaginal infection, contact lens intolerance, vomiting, alopecia,
dysmenorrhoea, ovarian cyst, fatigue, Rare (>1/10,000, <1/1,000): rash, urticaria, erythema
nodosum. Breast discharge may occur during use of Cerelle. Rarely ectopic pregnancies have
been reported. Please refer to the relevant SmPC on each product in relation to other side
effects. Overdose: There have been no reports of serious adverse effects from overdose. NHS
Price: Rigevidon 3 x 21 tablets £1.89; Gedarel 30/150 3 x 21 tablets £4.93; Gedarel 20/150
3 x 21 tablets £5.98; Millinette 30/75 3 x 21 tablets £4.85; Millinette 20/75 3 x 21 tablets £6.37;
TriRegol 3 x 21 tablets £2.87; Cerelle 3 x 28 tablets £4.30. Legal category: All POM.
Authorisation numbers: Rigevidon 17550/0032; Gedarel 30/150 PL 04854/0061; Gedarel
20/150 PL 04854/0060; Millinette 30/75 PL 17550/0043; Millinette 20/75 PL 17550/0042;
TriRegol PL 17550/0031; Cerelle PL 20154/0029. Marketing Authorisation Holder:
Rigevidon: Gedeon Richter France, 1 – 3 rue Caumartin, 75009 Paris, France. Millinette 30/75,
Millinette 20/75, TriRegol: Medimpex France SA, 1 – 3 rue Caumartin, 75009 Paris, France.
Gedarel 30/150, Gedarel 20/150, Cerelle: Gedeon Richter Plc. 1103 Budapest, Gyömrői út,
19-21, Hungary. Further information is available on request from Consilient Health (UK) Ltd,
500 Chiswick High Road, London W4 5RG, UK on 020 8956 2310. CH-OCs-1109-11/2012
Date of preparation of prescribing information: December 2012
Adverse events should be reported. Reporting forms and information can
be found at www.mhra.gov.uk/yellowcard. Adverse events should also be
reported to Consilient Health (UK) Ltd, 500 Chiswick High Road, London
W4 5RG, UK on 020 8956 2310.
CH-OCs-623b-08/2012 Date of Preparation: December 2012
For further information and to download the free ‘My OC’ reminder app, please visit: www.knowyourcontraceptives.co.uk